Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Nucynta tapentadol hydrochloride pain, severe Do not reimburse Complete
Nucynta CR Tapentadol Pain, moderate to moderately severe Do not list Complete
Nurtec ODT rimegepant Migraine, prevention Withdrawn
NuvaRing Etonogestrel/ethinyl estradiol Contraceptive, ring List with clinical criteria and/or conditions Complete
Ocaliva Obeticholic Acid Primary Biliary Cholangitis Reimburse with clinical criteria and/or conditions Complete
Ocrevus ocrelizumab multiple sclerosis, relapsing Reimburse with clinical criteria and/or conditions Complete
Ocrevus ocrelizumab Primary progressive multiple sclerosis Reimburse with clinical criteria and/or conditions Complete
Odefsey emtricitabine/rilpivirine/ tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Odomzo Sonidegib Basal Cell Carcinoma Do not reimburse Complete
Ofev nintedanib chronic fibrosing interstitial lung diseases Reimburse with clinical criteria and/or conditions Complete